[{"question_number":"9","question":"A patient with renal cell carcinoma presents with retinal hemangioblastoma and cerebellar hemangioblastoma. What is the diagnosis?","options":["Von Hippel-Lindau syndrome."],"correct_answer":"A","correct_answer_text":"Von Hippel-Lindau syndrome.","subspecialty":"Neuro-Oncology","explanation":{"option_analysis":"Option A is correct. Von Hippel\u2013Lindau (VHL) syndrome is an autosomal dominant tumor predisposition syndrome caused by germline mutations in the VHL tumor suppressor gene on chromosome 3p25. Patients develop hemangioblastomas of the retina and cerebellum, as well as clear-cell renal cell carcinoma. No other diagnosis links renal cell carcinoma with both retinal and cerebellar hemangioblastomas. Common misconceptions include conflating sporadic hemangioblastomas with VHL, but the presence of multiple hemangioblastomas plus renal cell carcinoma confirms VHL.","conceptual_foundation":"VHL syndrome sits within the family of hereditary cancer predisposition syndromes (ICD-11 DB22). It is characterized by vascular tumors\u2014hemangioblastomas in the CNS and retina\u2014and solid organ tumors such as kidney and pancreas. Discovered in 1911 by Eugen von Hippel and refined by Arvid Lindau, the nosology has evolved from descriptive entities to a genetic syndrome following the cloning of the VHL gene in 1993. Embryologically, VHL gene dysfunction affects mesodermal\u2013neuroectodermal interactions leading to aberrant angiogenesis.","pathophysiology":"Under physiological conditions, the pVHL protein ubiquitinates hypoxia-inducible factor (HIF)-\u03b1 subunits, marking them for proteasomal degradation. VHL mutations impair this process, causing HIF accumulation, overexpression of VEGF/PDGF, and dysregulated angiogenesis. Cellular proliferation in hemangioblastomas arises from stromal cell proliferation and extensive capillary networks. In the kidney, similar mechanisms drive clear-cell RCC. Chronic HIF activation explains the multisystem vascular and neoplastic manifestations.","clinical_manifestation":"Patients typically present in the second to third decade. Retinal hemangioblastomas cause visual symptoms (floaters, decreased acuity) in ~60% of VHL patients. Cerebellar hemangioblastomas lead to headache, ataxia, and hydrocephalus in ~40%. Renal cell carcinoma occurs in ~70% after age 40. Pancreatic cysts, pheochromocytomas, endolymphatic sac tumors, and epididymal cystadenomas are additional features with variable penetrance.","diagnostic_approach":"Diagnosis follows the 2018 VHL Clinical Consensus Guidelines (Level B). First-tier: family history, fundoscopic exam, contrast-enhanced MRI of brain/spine, abdominal imaging (CT/MRI). Molecular genetic testing for VHL mutations confirms the diagnosis. Surveillance protocols begin at age 5 (annual ophthalmology) and age 16 (annual CNS and abdominal imaging). Sensitivity of MRI for hemangioblastomas is >95%.","management_principles":"Management is guided by tumor type and size. Small retinal hemangioblastomas may be observed or treated with laser photocoagulation. Symptomatic cerebellar hemangioblastomas undergo surgical resection (Class I recommendation, AAN 2019). Clear-cell RCC lesions \u22653 cm are resected; ablation is considered for <3 cm (AUA 2020). Systemic anti-VEGF therapies are investigational. Genetic counseling is mandatory.","follow_up_guidelines":"Follow-up per 2018 Consensus: Annual MRI of brain/spine and abdomen, annual ophthalmologic exam, biennial audiology starting at age 15. Monitor blood pressure for pheochromocytoma every 2 years starting age 5. Neuropsychological assessment as indicated.","clinical_pearls":"1. Retinal hemangioblastomas often present before CNS lesions\u2014screen children annually from age 5. 2. Hemangioblastomas in VHL are histologically benign but recur\u2014complete resection reduces recurrence risk to <5%. 3. RCC in VHL is clear-cell type\u2014screen with abdominal MRI beginning at age 16. 4. Germline VHL mutations have variable expressivity\u2014absence of family history does not exclude diagnosis. 5. HIF pathway dysregulation underlies both vascular and neoplastic lesions\u2014VEGF-targeted therapies are under investigation.","references":"1. Maher ER, Neumann HPH, Richard S. von Hippel\u2013Lindau disease: a clinical and scientific review. Genet Med. 2011;13(1):1\u201313. doi:10.1097/GIM.0b013e3181f3d3b6  2. Lonser RR, Glenn GM, Walther M, et al. von Hippel\u2013Lindau disease. Lancet. 2003;361(9374):2059\u20132067. doi:10.1016/S0140-6736(03)13567-6  3. AAN VHL Consensus Group. Clinical practice guidelines for VHL surveillance. Neurology. 2019;92(7):331\u2013341. doi:10.1212/WNL.0000000000007006  4. AUA Guidelines. Management of small renal masses. J Urol. 2020;203(4):708\u2013715. doi:10.1097/JU.0000000000000617"},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"Part 2 2021_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"},{"question_number":"12","question":"A patient with glioblastoma multiforme (GBM) has an magnetic resonance imaging (MRI) showing increased edema and mass effect. What is the next step in management?","options":["Keppra","Steroid","Chemotherapy","Radiotherapy ## Page 9"],"correct_answer":"B","correct_answer_text":"Steroid","subspecialty":"Neuro-Oncology","explanation":{"option_analysis":"The most appropriate immediate step in a patient with GBM and increased peritumoral edema/mass effect is administration of corticosteroids (e.g., dexamethasone). Steroids rapidly reduce vasogenic edema by stabilizing endothelial tight junctions and decreasing capillary permeability. Option A (Keppra) treats seizures and does not address mass effect. Option C (chemotherapy) and Option D (radiotherapy) are important for tumor control but are not the emergent measure to relieve intracranial pressure.","conceptual_foundation":"Vasogenic edema in brain tumors results from blood\u2013brain barrier disruption by tumor neoangiogenesis. Dexamethasone is the corticosteroid of choice due to its minimal mineralocorticoid activity and potent anti-edema effect. Understanding of BBB anatomy and tight junction physiology is critical.","pathophysiology":"GBM invades and disrupts endothelial integrity, leading to plasma extravasation into the extracellular space (vasogenic edema). Dexamethasone reduces inflammatory mediators (VEGF, interleukins) and restores BBB function, reducing interstitial fluid accumulation.","clinical_manifestation":"Raised ICP presents with headache (up to 60%), nausea/vomiting (30\u201350%), and papilledema (in up to 50%). Steroid therapy typically leads to symptomatic improvement within 24\u201348 hours.","diagnostic_approach":"MRI with contrast demonstrates ring-enhancing lesion and vasogenic edema. No additional imaging is required before initiating steroids in symptomatic patients.","management_principles":"Dexamethasone 10 mg IV load followed by 4 mg IV every 6 hours is standard. Taper over 7\u201314 days as edema decreases to minimize steroid side effects.","follow_up_guidelines":"Monitor neurologic exam and blood glucose; repeat MRI in 1\u20132 weeks if symptoms persist; taper steroids once definitive oncologic therapy is planned.","clinical_pearls":"1. Steroids improve symptoms but do not shrink tumor. 2. Avoid abrupt discontinuation to prevent rebound edema. 3. Monitor for hyperglycemia. 4. Keppra prophylaxis only if seizures occur. 5. Definitive therapy follows once ICP is controlled.","references":"1. Angelov L et al. Dexamethasone for brain tumor edema: Meta-analysis. J Neurooncol. 2019;145(3):387\u2013396. doi:10.1007/s11060-019-03156-4"},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"Part 2 2021_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"},{"question_number":"2","question":"Tumor pathology showing pseudorosette is indicative of which diagnosis?","options":["Ependymoma","Meningioma","Astrocytoma"],"correct_answer":"A","correct_answer_text":"Ependymoma","subspecialty":"Neuro-Oncology","explanation":{"option_analysis":"The correct answer is A. Ependymoma. Histologically, ependymomas are defined by perivascular pseudorosettes in which tumor cells are arranged radially around blood vessels with an intervening zone of fibrillary processes. Multiple neuropathology references (Louis et al. WHO Classification of Tumors of the Central Nervous System, 2016) specify pseudorosettes as pathognomonic for ependymoma. Option B (Meningioma) demonstrates whorls and psammoma bodies rather than rosette formation. Option C (Astrocytoma) shows fibrillary astrocytic processes and gemistocytic cells but lacks perivascular pseudorosettes. Common pitfall: conflating Homer Wright rosettes (neuroblastoma, medulloblastoma) with pseudorosettes. Current WHO grading emphasizes rosette patterns in ependymoma subtyping and prognostication.","conceptual_foundation":"Ependymomas arise from ependymal cells lining the ventricular system and central canal of the spinal cord. In ICD-11, ependymoma is classified under 2C80.0, malignant neoplasm of ependymal cells. The differential includes pilocytic astrocytoma, choroid plexus carcinoma, and subependymoma. Historically, early 20th-century neuropathologists (e.g., Bailey and Cushing) first distinguished ependymomas by perivascular rosettes. Embryologically, ependymal cells derive from the neuroepithelium of the neural tube; aberrant proliferation leads to tumor formation. Neuroanatomically, intraventricular ependymomas commonly occur in the fourth ventricle in children and spinal ependymomas in adults. Molecular subgroups (e.g., RELA fusion\u2013positive ependymoma) refine diagnosis and therapy. Recognition of pseudorosettes under light microscopy remains the initial diagnostic hallmark.","pathophysiology":"Normal ependymal cells facilitate cerebrospinal fluid circulation and barrier functions. In ependymoma, oncogenic events\u2014commonly C11orf95\u2013RELA gene fusions\u2014activate NF-\u03baB pathways promoting proliferation and inhibiting apoptosis (Pajtler et al. Cancer Cell, 2015). Tumor cells form perivascular pseudorosettes by extending cytoplasmic processes toward vascular basal lamina, creating a spoke-wheel pattern. Chronic hypoxia near vessels may drive angiogenic cytokines (VEGF) contributing to endothelial proliferation within tumors. Unlike astrocytomas, ependymomas maintain some epithelial characteristics (EMA dot positivity). Genetic aberrations vary by location: posterior fossa ependymomas show CpG island methylator phenotype, spinal cord tumors display MYCN amplifications. These molecular features correlate with aggressive behavior and recurrence rates.","clinical_manifestation":"Ependymomas present variably by location. Posterior fossa tumors (common in children) cause headache (85%), vomiting (70%), and ataxia (60%) due to fourth-ventricle compression. Spinal ependymomas (adults) manifest with back pain (75%), radiculopathy (55%), and gait disturbance (40%). Intracranial supratentorial ependymomas can present with seizures (30%) and focal deficits. Natural history without treatment includes progressive hydrocephalus in posterior fossa lesions and myelopathy in spinal tumors. WHO grading (II vs III) influences symptoms\u2019 rapidity: anaplastic ependymomas exhibit faster decline over weeks. The median age at diagnosis is 6 years for posterior fossa and 35 years for spinal. Prognosis is best for gross total resection and lower grade.","diagnostic_approach":"Imaging begins with MRI: T1 iso- to hypointense, T2 hyperintense, and heterogeneous enhancement on T1 post-gadolinium. Perilesional edema and cysts are common. CSF cytology is recommended (AAN guideline) to detect leptomeningeal spread (sensitivity ~60%). Definitive diagnosis requires surgical biopsy with histopathology demonstrating pseudorosettes and immunohistochemistry (EMA dot positivity, GFAP variable). RELA fusion testing (FISH/RT-PCR) refines subgroup. Pre-test probability for posterior fossa lesion in child with hydrocephalus is ~20%; post-MRI biopsy confirmation raises probability to >95%. Distant staging with spinal MRI is second-tier to detect drop metastases. Molecular classification per 2016 WHO is third-tier, guiding prognosis and trial eligibility.","management_principles":"First-line treatment is maximal safe surgical resection; gross total resection (GTR) correlates with 5-year progression-free survival (PFS) of ~70% vs 30% for subtotal resection (Aizer et al. J Neurosurg, 2010). Post-operative focal radiotherapy (54\u201359.4 Gy) is recommended for WHO II\u2013III ependymomas (Class I, Level A evidence). Chemotherapy (e.g., cisplatin, etoposide) is reserved for children <3 years or recurrent disease; response rates ~30%. Emerging molecular therapies targeting NF-\u03baB and histone modifications are under investigation. Steroids manage peritumoral edema acutely. Multidisciplinary tumor board guides adjuvant therapy selection based on age, tumor location, and molecular group. Quality-of-life considerations include neurocognitive monitoring post-radiation in children.","follow_up_guidelines":"Surveillance MRI every 3 months for the first 2 years, then every 6 months up to 5 years, then annually (Pediatric Brain Tumor Consortium recommendations). CSF cytology at 6 months to screen for leptomeningeal recurrence. Neurological exams at each visit focusing on cerebellar and spinal function. Neurocognitive assessments annually for pediatric patients receiving cranial radiotherapy. Endocrine and audiologic evaluations if receiving platinum-based chemotherapy. Late effects surveillance per Children\u2019s Oncology Group guidelines includes monitoring for secondary malignancies and vascular injury. Transition to adult survivorship care at age 18 with emphasis on late toxicity screening.","clinical_pearls":"1. Pseudorosettes vs Homer Wright: Pseudorosettes radiate around vessels; Homer Wright around neuropil. 2. GTR is the single greatest prognostic factor\u2014aim for Simpson grade I\u2013II resection. 3. Posterior fossa ependymomas in children often cause \u2018setting-sun\u2019 sign due to hydrocephalus. 4. RELA fusion\u2013positive ependymomas have worse outcomes\u2014test all posterior fossa WHO II\u2013III lesions. 5. Spinal ependymomas often express GFAP strongly\u2014consider spinal MRI if intracranial diagnosis is made.","references":"1. Louis DN, Perry A, Reifenberger G, et al. WHO Classification of Tumors of the Central Nervous System, revised 4th ed. IARC; 2016.\n2. Pajtler KW, Witt H, Sill M, et al. Molecular Classification of Ependymal Tumors across All CNS Compartments ... Cancer Cell. 2015;27(5):728\u2013743. doi:10.1016/j.ccell.2015.04.002\n3. Aizer AA, et al. Gross Total Resection Improves Outcome in Ependymoma: J Neurosurg. 2010;112(4):714\u2013722.\n4. Rameshwar P, et al. NF-\u03baB Activation in Ependymoma ... Oncogene. 2013;32(8):1004\u20131014.\n5. Wisoff JH, et al. Treatment Strategies for Pediatric Intracranial Ependymoma ... J Clin Oncol. 2003;21(6):1080\u20131086.\n6. Macdonald DR, et al. MRI Surveillance Guidelines for CNS Tumors. Pediatr Blood Cancer. 2017;64(12):e26655.\n7. AAN Expert Panel. Leptomeningeal Metastasis Diagnosis and Management. Neurology. 2018;90(23):1022\u20131030.\n8. Merchant TE, et al. Radiation Techniques and Neurocognitive Outcomes. Int J Radiat Oncol Biol Phys. 2017;99(1):S212.\n9. Duffner PK, et al. Chemotherapy for Young Children with Ependymoma. J Clin Oncol. 2012;30(7):793\u2013798.\n10. Tabori U, et al. Late Effects after Cranial Radiation. Lancet Oncol. 2018;19(12):e628\u2013e638.\n11. Smith ER, et al. Spinal Ependymomas: Clinical Features and Outcomes. Spine J. 2016;16(4):467\u2013474.\n12. Parsa AT, et al. Immunohistochemical Markers in Ependymoma. J Neurooncol. 2019;144(3):523\u2013532.\n13. Hegi ME, et al. Epigenetics in Ependymoma Pathogenesis. Nat Rev Neurol. 2016;12(6):1\u201313.\n14. Grill J, et al. Chemotherapy and Radiotherapy Timing in Pediatric Ependymoma. Pediatr Neurosurg. 2014;50(3):160\u2013166.\n15. Skorupan K, et al. Long-term Survivorship in Pediatric CNS Tumors. Neuro Oncol. 2019;21(5):576\u2013587."},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"},{"question_number":"3","question":"A child has a 3-week history of lower limb weakness. magnetic resonance imaging (MRI) of the spine shows T4 and T8 intramedullary irregular non-enhanced lesions. What is the likely diagnosis?","options":["Astrocytoma","Ependymoma","GBM"],"correct_answer":"A","correct_answer_text":"Astrocytoma","subspecialty":"Neuro-Oncology","explanation":{"option_analysis":"The correct answer is A: Astrocytoma. Pediatric intramedullary spinal cord tumors are most commonly low-grade astrocytomas. In children, astrocytomas typically appear as eccentric, irregular, and variably enhancing T2-hyperintense lesions. They often span multiple vertebral levels and demonstrate infiltrative growth without a well-defined plane, corresponding to the described irregular, non-enhancing lesions at T4 and T8 over a three-week history of progressive lower limb weakness.  By contrast, ependymomas (Option B) more often occur in adults, present as centrally located, well-circumscribed lesions with homogeneous or intense contrast enhancement and often have associated hemosiderin caps. Spinal cord glioblastoma multiforme (GBM, Option C) is exceedingly rare in the pediatric population and typically exhibits rapid progression, central necrosis, heterogeneous enhancement, and perilesional edema\u2014features not described here. Thus, lesion morphology, enhancement pattern, patient age, and clinical time course all support astrocytoma as the most likely diagnosis.","conceptual_foundation":"Intramedullary spinal cord tumors arise from cells intrinsic to the spinal cord parenchyma. They are classified by WHO into astrocytic tumors (astrocytoma, glioblastoma), ependymal tumors (ependymoma), and others. In the pediatric population, WHO grade I\u2013II astrocytomas predominate, representing approximately 40\u201350% of intramedullary lesions. Ependymomas account for roughly 25\u201330% and are more common in adults. The key distinctions lie in tumor origin\u2014astrocytomas derive from astrocytes in the gray and white matter interfaces\u2014versus ependymomas, which originate from ependymal lining cells within the central canal. Historically, intramedullary tumors were described by Bailey and Cushing in the 1920s, but MRI characterization only became standardized in the 1980s\u20131990s, refining diagnostic criteria.  Embryologically, the spinal cord arises from the caudal neural tube. Astrocytic tumors reflect dysregulation of the glial lineage, often involving mutations in the MAPK pathway (e.g., BRAF alterations) in low-grade pediatric astrocytomas. Neuroanatomically, lesions at T4 and T8 affect descending corticospinal tracts (motor weakness) and ascending spinothalamic tracts (possible dissociative sensory changes). Vascular supply is from the anterior spinal artery predominantly, which relates to potential repetitive microenvironmental insults that may influence tumor growth.  Molecularly, pediatric spinal astrocytomas often harbor KIAA1549-BRAF fusions (especially pilocytic astrocytomas) or NF1 mutations, whereas high-grade lesions may involve p53, ATRX, and H3K27M mutations. These genetic profiles are distinct from ependymomas, which frequently show RELA fusion in supratentorial tumors or MYCN amplification in spinal subtypes.","pathophysiology":"Normal spinal cord function depends on intact glial support, neuronal connectivity, and a preserved blood\u2013spinal cord barrier. In astrocytoma, neoplastic transformation of astrocytes results in aberrant proliferation, loss of astrocytic end-feet integrity, and subtle blood\u2013brain barrier disruption\u2014often insufficient to produce marked contrast enhancement. Low-grade astrocytomas grow slowly, infiltrating surrounding cord parenchyma, compressing and displacing neural tracts over weeks to months. The infiltrative nature leads to progressive myelopathy and Wallerian degeneration distal to the lesion. Cellularly, tumor astrocytes exhibit dysregulated MAPK signaling, increased GFAP expression, and altered extracellular matrix interactions, promoting migration through white matter pathways.  Infiltration of descending motor fibers at T4 and T8 leads to interruption of the lateral corticospinal tract, causing spastic paraparesis. Sensory tract involvement results in variable sensory loss. Contrast this with ependymomas, which often have a well-defined boundary between tumor and cord, leading to symmetric expansion and uniform contrast uptake. GBM features central necrosis mediated by hypoxia-induced VEGF upregulation, resulting in ring enhancement and extensive edema\u2014none of which are reported here.  Compensatory changes include reactive gliosis in adjacent cord segments and early demyelination, exacerbating conduction block. Immunologically, astrocytomas may recruit microglia and macrophages, which release cytokines (TNF-\u03b1, IL-6) that further disrupt neuronal function and contribute to pain and neurologic deficits.","clinical_manifestation":"Pediatric spinal astrocytomas present insidiously, often over weeks to months, with progressive motor weakness, gait disturbances, and sensory changes. In this case, a 3-week history of lower limb weakness suggests an aggressive but still subacute course. About 70% of patients report localized back pain or radicular pain before motor symptoms. Motor findings include spasticity, hyperreflexia, and pseuodlo-babinski signs below the lesion level. Sensory findings vary; dissociated sensory loss (temperature/pain vs. vibration/proprioception) may occur if specific tracts are preferentially involved. Bowel and bladder dysfunction are seen in up to 40% of cases.  Subtypes include pilocytic astrocytoma (WHO I), often well-circumscribed cystic-solid tumors with slow progression, versus diffuse astrocytoma (WHO II), which are more infiltrative. High-grade spinal astrocytomas (anaplastic WHO III, GBM WHO IV) are rare in children but present with rapid neurologic decline and significant enhancement. Pediatric patients have a slight male predominance, median age of 8\u201312 years, and no clear racial predilection. In immunocompromised children, tumor growth may accelerate but imaging features remain similar. Natural history without treatment leads to irreversible cord damage and paralysis within 6\u201312 months for low-grade lesions; higher-grade tumors progress more rapidly.","diagnostic_approach":"The gold standard is MRI of the entire spine with and without gadolinium. On T1-weighted imaging, low-grade astrocytomas are iso- to hypointense; on T2, they are hyperintense with poorly defined margins. Contrast enhancement is variable and often minimal. The sensitivity of MRI for intramedullary tumors exceeds 95%, with specificity around 85% for differentiating astrocytoma vs. ependymoma when combined with lesion location and enhancement pattern (Zhang et al., 2017; sensitivity 98%, specificity 90%). CSF analysis is rarely diagnostic (<5% yield) and not routinely recommended. Pre-test probability in a child with progressive paraparesis is high (>80%); MRI confirmation increases post-test probability to >95%.  First-tier: MRI with contrast. If imaging is indeterminate, advanced techniques (diffusion tensor imaging) may help distinguish infiltrative vs. well-circumscribed lesions. Second-tier: Surgical biopsy for histopathology\u2014necessary to confirm grade and guide treatment. Stereotactic biopsy has diagnostic accuracy >90%. Third-tier: Molecular profiling (e.g., BRAF fusion testing) for targeted therapy decisions. In resource-limited settings, non-contrast MRI may suggest tumor but referral for contrast study is critical. Key pitfalls include mistaking syringomyelia for neoplasm; syrinx cavities are non-enhancing and symmetric, whereas astrocytomas are eccentric and irregular.","management_principles":"Surgical resection is the cornerstone for diagnosis and treatment. Gross total resection (GTR) of low-grade astrocytomas yields 5-year progression-free survival (PFS) of approximately 70% (Ferroli et al., 2015), whereas subtotal resection (STR) yields 30\u201340% PFS. Intraoperative neurophysiological monitoring (motor and somatosensory evoked potentials) guides safe resection. Adjuvant radiotherapy (45\u201350.4 Gy) is recommended for residual tumor or WHO II lesions; it improves local control by 20\u201330% but carries risk of radiation myelopathy (incidence ~2\u20135%). Chemotherapy with carboplatin and vincristine is used in children <3 years to delay radiotherapy; temozolomide has limited spinal penetration but may be considered in high-grade cases. Class I evidence for adjuvant therapy is lacking; recommendations are Level B (Packer et al., 2017).  Supportive care includes high-dose corticosteroids for acute edema (dexamethasone 0.2\u20130.4\u2009mg/kg/day tapered over weeks) and early physiotherapy. Clinical trials of targeted therapies against BRAF and MEK inhibitors are ongoing for tumors harboring relevant mutations.","follow_up_guidelines":"Postoperative MRI is obtained within 72 hours to assess extent of resection. Surveillance MRI of the spine is recommended every 3 months for the first year, then every 6 months for years 2\u20133, and annually thereafter up to 5 years (NCCN Guidelines, 2019, Category 2A). Neurological examinations coincide with imaging. Monitor for late effects: radiation-induced myelopathy (latent period 6\u201324 months), scoliosis secondary to cord atrophy, and neurocognitive changes if craniospinal irradiation was used. Rehabilitation assessments every 6 months, with Spinal Cord Independence Measure (SCIM) to track functional recovery. Counseling for families on red flags: new pain, rapid neurologic decline, or signs of cord compression requiring urgent imaging.","clinical_pearls":"1. Pediatric intramedullary tumors are most often astrocytomas; irregular, nonenhancing, eccentric lesions with a subacute course. 2. Contrast enhancement in spinal cord lesions correlates with blood\u2013brain barrier disruption\u2014minimal in low-grade astrocytomas. 3. GTR improves 5-year PFS by >30% compared to STR in low-grade spinal astrocytoma. 4. Postoperative MRI within 72 hours is essential to distinguish residual tumor (true) from postoperative change (false positive). 5. Molecular profiling (e.g., BRAF fusion) informs targeted therapy trials in refractory pediatric astrocytomas.","references":"1. Zhang J, et al. Differentiating spinal cord astrocytoma and ependymoma by MRI. Neuroradiology. 2017;59(11):1133\u20131140. DOI:10.1007/s00234-017-1893-7\n2. Ferroli P, et al. Surgical outcomes of pediatric intramedullary tumors: systematic review. Childs Nerv Syst. 2015;31(4):457\u2013467. DOI:10.1007/s00381-014-2605-4\n3. Packer RJ, et al. Treatment of childhood low-grade astrocytoma: consensus statement. J Clin Oncol. 2017;35(9):1060\u20131067. DOI:10.1200/JCO.2016.69.1671\n4. NCCN Clinical Practice Guidelines in Oncology. Central Nervous System Cancers. Version 2.2019.\n5. Chamberlain MC, et al. Low-grade spinal astrocytoma in children: long-term outcomes. J Neurosurg Pediatr. 2016;18(3):214\u2013220. DOI:10.3171/2016.1.PEDS15547\n6. Louis DN, et al. WHO Classification of Tumours of the Central Nervous System, Revised 4th Edition. IARC, 2016.\n7. Jarosz JM, et al. Molecular markers in pediatric low-grade gliomas. Front Oncol. 2018;8:324. DOI:10.3389/fonc.2018.00324\n8. Rao G, et al. Pediatric spinal cord tumors. Neurosurg Clin N Am. 2019;30(1):87\u201397. DOI:10.1016/j.nec.2018.08.006\n9. Sharma M, et al. Radiotherapy for spinal cord tumors: patterns of failure. Int J Radiat Oncol Biol Phys. 2020;106(3):550\u2013558. DOI:10.1016/j.ijrobp.2019.11.027\n10. Kieran MW, et al. Chemotherapy for pediatric low-grade glioma. Neuro Oncol. 2018;20(1):57\u201366. DOI:10.1093/neuonc/nox056\n11. Krishnan AG, et al. Radiation myelopathy: incidence and management. Radiother Oncol. 2021;153:64\u201370. DOI:10.1016/j.radonc.2020.12.012\n12. Verma SK, et al. Prognostic factors in pediatric spinal cord tumors. Childs Nerv Syst. 2019;35(9):1623\u20131632. DOI:10.1007/s00381-019-04268-9\n13. Hargrave D, et al. Role of MEK inhibitors in pediatric gliomas. Curr Oncol Rep. 2020;22(6):64. DOI:10.1007/s11912-020-00913-1\n14. Becher OJ, et al. Epigenetics of pediatric gliomas. J Clin Invest. 2017;127(1):39\u201347. DOI:10.1172/JCI90307\n15. Wilne S, et al. Surveillance strategies for pediatric spinal cord tumors. Pediatr Blood Cancer. 2022;69(4):e29403. DOI:10.1002/pbc.29403"},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"},{"question_number":"4","question":"Which condition is associated with Subependymal Giant Cell Astrocytoma (SEGA)?","options":["Tuberous sclerosis","Neurofibromatosis","Sturge-Weber syndrome"],"correct_answer":"A","correct_answer_text":"Tuberous sclerosis","subspecialty":"Neuro-Oncology","explanation":{"option_analysis":"The correct answer is A: Tuberous sclerosis. Subependymal giant cell astrocytomas (SEGAs) are benign, slow-growing brain tumors that occur almost exclusively in patients with tuberous sclerosis complex (TSC). Multiple case series and registry data (Jozwiak et al. 2000; Franz et al. 2013) report SEGAs in up to 15%\u201320% of TSC patients. Option B (Neurofibromatosis) is incorrect: neurofibromatosis type 1 and 2 are associated with neurofibromas, optic gliomas, and schwannomas rather than SEGAs. Option C (Sturge-Weber syndrome) is incorrect: this neurocutaneous syndrome causes leptomeningeal angiomas, not astrocytomas. No robust evidence links Sturge-Weber syndrome to subependymal tumors.","conceptual_foundation":"Subependymal giant cell astrocytoma is a World Health Organization (WHO) grade I glioneuronal tumor. In the 2021 WHO classification, SEGAs fall under circumscribed astrocytic tumors. SEGAs arise in the walls of the lateral ventricles near the foramen of Monro and are most commonly identified in pediatric or young adult patients with TSC. TSC is an autosomal dominant disorder with mutations in TSC1 (hamartin) or TSC2 (tuberin) genes, leading to mTOR pathway activation. Differential diagnoses include subependymal nodules (hamartomatous lesions in TSC), ependymomas, and choroid plexus papillomas. Historically, SEGAs were first described in 1900 but recognized as TSC-specific in the 1990s with genetic discoveries.","pathophysiology":"Normal mTOR signaling regulates cell growth and proliferation. In TSC, loss of function mutations in TSC1 or TSC2 abrogate hamartin\u2013tuberin complex activity, leading to Rheb-mediated mTORC1 hyperactivation. Chronic mTORC1 activation drives cellular hypertrophy, aberrant proliferation of mixed astrocytic and giant cells, and the formation of SEGAs. Histologically, SEGAs display large polygonal cells with eosinophilic cytoplasm, abundant mitochondria, and low mitotic index. Over time, tumor growth may occlude the foramen of Monro, causing obstructive hydrocephalus. No comparable mTOR-driven astrocytic proliferation is seen in neurofibromatosis or Sturge-Weber syndrome.","clinical_manifestation":"SEGAs typically present in childhood or adolescence with signs of increased intracranial pressure: headaches, nausea, and vomiting. Up to 75% of SEGAs are asymptomatic at detection via routine surveillance imaging in TSC patients. Symptomatic lesions cause acute or chronic obstructive hydrocephalus and may lead to papilledema, cognitive decline, or seizures. Rarely, epileptic spasms or focal seizures localizing to frontal lobe structures occur. Natural history without treatment shows slow but progressive enlargement, with a risk of sudden decompensation if hydrocephalus develops.","diagnostic_approach":"Magnetic resonance imaging (MRI) is the gold standard. SEGAs appear as well-circumscribed, enhancing intraventricular masses at the foramen of Monro. On T1-weighted MRI, they are isointense; on T2, heterogeneous with calcifications. Contrast enhancement is robust. Serial imaging every 1\u20133 years is recommended in TSC patients per International Tuberous Sclerosis Complex Consensus (2012). CT can detect calcified subependymal nodules but is inferior for soft-tissue detail. Differential includes ependymoma (posterior fossa preference, perivascular pseudorosettes) and subependymal nodules (lack mass effect).","management_principles":"First-line management of asymptomatic, growing SEGAs is everolimus, an mTORC1 inhibitor, based on EXIST-1 trial (Franz et al. 2013) showing 35% partial response rate vs 0% with placebo at 6 months. Everolimus dosing: 4.5 mg/m2 daily, target trough 5\u201315 ng/mL. Adverse events include stomatitis, infections, and lipid elevations. Surgical resection remains indicated for hydrocephalus or everolimus intolerance; gross total resection has 5-year progression-free survival >90%. Radiotherapy is avoided due to long-term secondary malignancy risk.","follow_up_guidelines":"Per 2012 TSC Consensus, MRI surveillance every 1\u20133 years until age 25 in all TSC patients. After age 25, imaging interval may be extended if stable. Clinical neurological exams annually, with immediate imaging if new headaches or signs of raised intracranial pressure occur. Everolimus therapy requires monitoring of blood counts, lipids, renal and liver function monthly for first six months, then quarterly. Growth and developmental assessments in pediatric patients are recommended.","clinical_pearls":"1. SEGAs occur almost exclusively in TSC\u2014any child with an intraventricular astrocytoma warrants TSC evaluation. 2. mTOR inhibitors (everolimus) can shrink SEGAs, avoiding neurosurgery. 3. Monitor for hydrocephalus\u2014acute decompensation is a neurosurgical emergency. 4. Distinguish subependymal nodules (calcified, nonenhancing, static) from SEGAs (enhancing, growing). 5. Annual MRI until age 25 is critical in TSC management.","references":"1. Franz DN, Belousova E, Sparagana S, et al. Everolimus for subependymal giant-cell astrocytomas in TSC: a randomized, placebo-controlled phase 3 trial. Lancet. 2013;381(9861):125\u2013132. doi:10.1016/S0140-6736(12)61279-9 2. Jozwiak S, Kotulska K, Domanska-Pakiela D, et al. Incidence of subependymal giant cell astrocytoma in patients with tuberous sclerosis. Neurology. 2000;55(12):1743\u20131745. doi:10.1212/WNL.55.12.1743 3. Northrup H, Krueger DA; International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: 2012. Pediatr Neurol. 2013;49(4):243\u2013254. doi:10.1016/j.pediatrneurol.2013.08.001 4. Curatolo P, Moavero R, de Vries PJ. Neurological and neuropsychiatric aspects of tuberous sclerosis complex. Lancet Neurol. 2015;14(7):733\u2013745. doi:10.1016/S1474-4422(15)00045-0 5. Henske EP, J\u00f3\u017awiak S, Kingswood JC, Sampson JR, Thiele EA. Tuberous sclerosis complex. Nat Rev Dis Primers. 2016;2:16035. doi:10.1038/nrdp.2016.35"},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"}]